Overview Dividends

(AVTR) Avantor - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05352A1007

Chemicals, Reagents, Labware, Equipment, Services

AVTR EPS (Earnings per Share)

EPS Growth (3y CAGR): -12.74%
EPS Trend (3y Corr): -73.5%

Last SUE: 0.00σ

AVTR Revenue

Revenue Growth (3y CAGR): -3.58%
Revenue Trend (3y Corr): -85.3%

Last SUE: -1.36σ

Risk via 10d forecast
Volatility	69.0%
Value at Risk 5%th	102%
Relative Tail Risk	-10.17%

Reward TTM
Sharpe Ratio	-1.01
Alpha	-63.31

Character TTM
Hurst Exponent	0.398
Beta	1.104
Beta Downside	1.035

Drawdowns 3y
Max DD	60.72%
Mean DD	22.38%
Median DD	17.53%

Description: AVTR Avantor November 03, 2025

Avantor Inc. (NYSE:AVTR) supplies mission-critical materials, consumables, equipment, and services to biopharma, healthcare, education, government, advanced-technology, and applied-materials customers across the Americas, Europe, Asia, the Middle East, and Africa. Its portfolio spans purity chemicals, reagents, lab supplies, customized excipients and single-use assemblies, chromatography resins, analytical kits, as well as filtration, virus-inactivation, incubators, ultra-low-temperature freezers, biosafety cabinets, and peristaltic pumps.

The company also delivers on-site lab and production support, procurement and sourcing, biopharmaceutical scale-up, and a suite of scientific-research services-including DNA extraction, bioreactor servicing, compound management, clean-room monitoring, and sanitization. Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor operates under the “Life Sciences Tools & Services” GICS sub-industry.

Key financial metrics (FY 2023) show revenue of roughly $4.1 billion, an adjusted EBITDA margin near 13 %, and a 12-month forward-PE of about 18×, reflecting solid pricing power amid rising demand for biologics and personalized medicine. The sector’s growth is underpinned by expanding global biopharma pipelines, increased clinical-trial activity, and heightened focus on supply-chain resilience for critical reagents.

For a deeper quantitative assessment of Avantor’s valuation relative to peers, you may find the ValueRay platform’s forward-cash-flow model useful.

AVTR Stock Overview

Market Cap in USD	7,977m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2019-05-17
Return 12m vs S&P 500	-52.9%
Analyst Rating	3.76 of 5

AVTR Dividends

Currently no dividends paid

AVTR Growth Ratios

Metric	Value
CAGR 3y	-19.49%
CAGR/Max DD Calmar Ratio	-0.32
CAGR/Mean DD Pain Ratio	-0.87
Current Volume	11379k
Average Volume	10000.4k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-82.2m TTM) > 0 and > 6% of Revenue (6% = 394.5m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -1.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 11.27% (prev 12.83%; Δ -1.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 644.4m > Net Income -82.2m (YES >=105%, WARN >=100%)

Net Debt (3.61b) to EBITDA (644.6m) ratio: 5.59 <= 3.0 (WARN <= 3.5)

Current Ratio 1.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (681.7m) change vs 12m ago -0.19% (target <= -2.0% for YES)

Gross Margin 33.13% (prev 33.53%; Δ -0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.64% (prev 53.11%; Δ 0.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.36 (EBITDA TTM 644.6m / Interest Expense TTM 174.7m) >= 6 (WARN >= 3)

Altman Z'' 1.96

(A) 0.06 = (Total Current Assets 2.26b - Total Current Liabilities 1.52b) / Total Assets 11.68b

(B) 0.14 = Retained Earnings (Balance) 1.62b / Total Assets 11.68b

(D) 0.91 = Book Value of Equity 5.57b / Total Liabilities 6.11b

Total Rating: 1.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.29

1. Piotroski 3.50pt = -1.50

2. FCF Yield 4.52% = 2.26

3. FCF Margin 7.96% = 1.99

4. Debt/Equity 0.69 = 2.27

5. Debt/Ebitda 5.59 = -2.50

6. ROIC - WACC (= -4.75)% = -5.93

7. RoE -1.38% = -0.23

8. Rev. Trend -85.25% = -6.39

9. EPS Trend -73.55% = -3.68

What is the price of AVTR shares?

As of November 18, 2025, the stock is trading at USD 10.88 with a total of 11,378,997 shares traded.
Over the past week, the price has changed by -5.39%, over one month by -26.39%, over three months by -14.73% and over the past year by -46.09%.

Is AVTR a buy, sell or hold?

Avantor has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold AVTR.

Strong Buy: 6
Buy: 4
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the AVTR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	13.6	25.4%
Analysts Target Price	13.6	25.4%
ValueRay Target Price	8.8	-19.5%

AVTR Fundamental Data Overview November 17, 2025

Market Cap USD = 7.98b (7.98b USD * 1.0 USD.USD)
P/E Forward = 11.9332
P/S = 1.2132
P/B = 1.393
Beta = 0.93
Revenue TTM = 6.58b USD
EBIT TTM = 236.8m USD
EBITDA TTM = 644.6m USD
Long Term Debt = 3.64b USD (from longTermDebt, last quarter)
Short Term Debt = 219.8m USD (from shortTermDebt, last quarter)
Debt = 3.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.61b USD (from netDebt column, last quarter)
Enterprise Value = 11.58b USD (7.98b + Debt 3.86b - CCE 251.9m)
Interest Coverage Ratio = 1.36 (Ebit TTM 236.8m / Interest Expense TTM 174.7m)
FCF Yield = 4.52% (FCF TTM 523.6m / Enterprise Value 11.58b)
FCF Margin = 7.96% (FCF TTM 523.6m / Revenue TTM 6.58b)
Net Margin = -1.25% (Net Income TTM -82.2m / Revenue TTM 6.58b)
Gross Margin = 33.13% ((Revenue TTM 6.58b - Cost of Revenue TTM 4.40b) / Revenue TTM)
Gross Margin QoQ = 32.42% (prev 32.92%)
Tobins Q-Ratio = 0.99 (Enterprise Value 11.58b / Total Assets 11.68b)
Interest Expense / Debt = 1.15% (Interest Expense 44.2m / Debt 3.86b)
Taxrate = -3.23% (negative due to tax credits) (22.3m / -689.5m)
NOPAT = 244.5m (EBIT 236.8m * (1 - -3.23%)) [negative tax rate / tax credits]
Current Ratio = 1.49 (Total Current Assets 2.26b / Total Current Liabilities 1.52b)
Debt / Equity = 0.69 (Debt 3.86b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 5.59 (Net Debt 3.61b / EBITDA 644.6m)
Debt / FCF = 6.89 (Net Debt 3.61b / FCF TTM 523.6m)
Total Stockholder Equity = 5.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.70% (Net Income -82.2m / Total Assets 11.68b)
RoE = -1.38% (Net Income TTM -82.2m / Total Stockholder Equity 5.98b)
RoCE = 2.46% (EBIT 236.8m / Capital Employed (Equity 5.98b + L.T.Debt 3.64b))
RoIC = 2.43% (NOPAT 244.5m / Invested Capital 10.04b)
WACC = 7.18% (E(7.98b)/V(11.84b) * Re(10.08%) + D(3.86b)/V(11.84b) * Rd(1.15%) * (1-Tc(-0.03)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.18%
[DCF Debug] Terminal Value 69.56% ; FCFE base≈613.0m ; Y1≈562.3m ; Y5≈502.0m
Fair Price DCF = 9.53 (DCF Value 6.50b / Shares Outstanding 681.8m; 5y FCF grow -10.37% → 3.0% )
EPS Correlation: -73.55 | EPS CAGR: -12.74% | SUE: 0.0 | # QB: 0
Revenue Correlation: -85.25 | Revenue CAGR: -3.58% | SUE: -1.36 | # QB: 0

Additional Sources for AVTR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle